Marcy S. Klevorn
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
SoundHound expands IoT reach with agentic AI. SoundHound is broadening its Internet of Things presence by deploying agentic AI across more devices. This move is relevant to Cerence as it highlights growing industry focus on AI-driven voice and interaction capabilities. While the news centers on a competitor, it underscores the competitive landscape in which Cerence operates.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Humana to drop 37 PPOs for 2027 Medicare Advantage plans. Humana announced it will discontinue 37 Preferred Provider Organization (PPO) plans for the 2027 Medicare Advantage enrollment period. The company noted that affected members may qualify for a Medigap open enrollment window without health questions. This structural change impacts the company's product lineup and member retention strategies for the upcoming year.
Transaction History
| NTRS | ▲ Buy | Grant | 65 | $11K | 10/1/2026 | View on chart |
| NTRS | ▲ Buy | Grant | 57 | $10K | 7/1/2026 | View on chart |
| NTRS | ▲ Buy | Grant | 35 | $6K | 4/21/2026 | View on chart |
| NTRS | ▲ Buy | Grant | 989 | $0 | 4/21/2026 | View on chart |
| NTRS | ▲ Buy | Grant | 60 | $8K | 4/1/2026 | View on chart |
| CRNC | ▲ Buy | Grant | 12,968 | $130 | 2/12/2026 | View on chart |
| NTRS | ▲ Buy | Grant | 61 | $8K | 1/1/2026 | View on chart |
| NTRS | ▲ Buy | Grant | 63 | $8K | 10/1/2025 | View on chart |
| NTRS | ▲ Buy | Grant | 61 | $8K | 7/1/2025 | View on chart |
| NTRS | ▲ Buy | Grant | 61 | $5K | 4/22/2025 | View on chart |
| NTRS | ▲ Buy | Grant | 1,902 | $0 | 4/22/2025 | View on chart |
| NTRS | ▲ Buy | Grant | 64 | $6K | 4/1/2025 | View on chart |
| CRNC | ▲ Buy | Grant | 9,955 | $100 | 2/13/2025 | View on chart |
| NTRS | ▲ Buy | Grant | 61 | $6K | 1/1/2025 | View on chart |
| NTRS | ▲ Buy | Grant | 70 | $6K | 10/1/2024 | View on chart |
| NTRS | ▲ Buy | Grant | 73 | $6K | 7/1/2024 | View on chart |
| NTRS | ▲ Buy | Grant | 70 | $6K | 4/16/2024 | View on chart |
| NTRS | ▲ Buy | Grant | 1,822 | $0 | 4/16/2024 | View on chart |
| NTRS | ▲ Buy | Grant | 53 | $5K | 4/1/2024 | View on chart |
| CRNC | ▲ Buy | Grant | 7,196 | $72 | 2/15/2024 | View on chart |
| NTRS | ▲ Buy | Grant | 55 | $5K | 1/1/2024 | View on chart |
| NTRS | ▲ Buy | Grant | 66 | $5K | 10/1/2023 | View on chart |
| NTRS | ▲ Buy | Grant | 61 | $5K | 7/1/2023 | View on chart |
| CRNC | ▲ Buy | Grant | 5,285 | $0 | 6/1/2023 | View on chart |
| NTRS | ▲ Buy | Grant | 51 | $4K | 4/25/2023 | View on chart |
| NTRS | ▲ Buy | Grant | 1,855 | $0 | 4/25/2023 | View on chart |
| NTRS | ▲ Buy | Grant | 39 | $3K | 4/1/2023 | View on chart |
| NTRS | ▲ Buy | Grant | 39 | $3K | 1/1/2023 | View on chart |
| NTRS | ▲ Buy | Grant | 40 | $3K | 10/1/2022 | View on chart |
| NTRS | ▲ Buy | Grant | 32 | $3K | 7/1/2022 | View on chart |
| NTRS | ▲ Buy | Grant | 30 | $3K | 4/26/2022 | View on chart |
| NTRS | ▲ Buy | Grant | 1,343 | $0 | 4/26/2022 | View on chart |
| NTRS | ▲ Buy | Grant | 20 | $2K | 4/1/2022 | View on chart |
| HUM | ▲ Buy | Option Exercise | 436 | $0 | 2/17/2022 | View on chart |
| NTRS | ▲ Buy | Grant | 19 | $2K | 1/1/2022 | View on chart |
| NTRS | ▲ Buy | Grant | 21 | $2K | 10/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Northern Trust Q3 Earnings Loom Amid Mixed Sector News
Northern Trust is approaching its third-quarter earnings release, with analysts focusing on revenue and EPS estimates. Recent reports indicate the stock has experienced a sharp decline, joining other financial peers in a downturn. While one firm reaffirmed a positive outlook citing the company's quality, the broader sector remains under pressure.
Northern Trust Q3 Earnings Loom Amid Mixed Sector News. Northern Trust is approaching its third-quarter earnings release, with analysts focusing on revenue and EPS estimates. Recent reports indicate the stock has experienced a sharp decline, joining other financial peers in a downturn. While one firm reaffirmed a positive outlook citing the company's quality, the broader sector remains under pressure.